Articles From: Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements to Regado Biosciences' REG2 Demonstrates Dose and Concentration-Dependent Suppression of Thrombin Generation


LAVAL, Quebec , June 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that, as promised, it has posted fact-based answers to refute misleading assertions made by Allergan, Inc. (NYSE: AGN) in its June 10 th presentation.
Sign-up for Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements investment picks
Deployment-ready Solution Built with Altera's Interlaken Look-Aside IP and Cavium's NEURON Search Processor SAN JOSE, Calif.
Sign-up for Altera and Cavium Deliver Pre-Verified Packet Classification Solution for Networking Appliances investment picks
CACI International Inc ( NYSE:CACI ) announced today that it has been awarded a $26.6 million contract award to provide Engineering and Technical Related Services (ETRS) in support of the Naval Surface Warfare Center Indian Head Explosive Ordnance Disposal Technology Division (NSWC IHEODTD). This contract, which is for one base year and two one-year options, was awarded under the SeaPort-e contract vehicle that CACI received in 2004.
Sign-up for CACI Awarded $26.6 Million Contract to Continue Engineering Support for U.S. Navy Weapons Systems investment picks
NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that a preclinical study in a mouse model of NASH (non-alcoholic steatohepatitis, or fatty liver disease) demonstrated that oral administration of the Company's lead galectin-3 inhibitor, GR-MD-02, resulted in significant disease improvement.
Sign-up for Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis investment picks
High value, high volume shipments of biologic material to be protected by comprehensive cold chain logistics solution LAKE FOREST, Calif.
Sign-up for Immudex Selects Cryoport to Manage Cold Chain Logistics of Biologic Samples and Proficiency Panels Worldwide investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today announced positive top-line results from a Phase 1 study of GEN-004, an investigational vaccine candidate designed to prevent infections from all serotypes of pneumococcus ( Streptococcus pneumoniae ), a major cause of infectious disease-related death globally.
Sign-up for Genocea Announces Positive Top-Line Phase 1 Results for Novel Universal Pneumococcus Vaccine Candidate GEN-004 investment picks
WIXOM, Mich., June 23, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) , a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, today announced that the FDA has approved the Company's Supplemental Abbreviated New Drug Application (sANDA) to manufacture Calcitriol.
Sign-up for Rockwell Medical Receives FDA Approval for Calcitriol investment picks
WINSTON-SALEM, N.C., June 23, 2014 (GLOBE NEWSWIRE) -- Primo Water Corporation (Nasdaq:PRMW) , a leading provider of multi-gallon purified bottled water, self-service refill water and water dispensers, today announced that it has entered into a new $35 million credit facility with Prudential Insurance Company of America and its affiliates.
Sign-up for Primo Water Enters Into New $35 Million Credit Facility investment picks
SAN ANTONIO , June 23, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, releases the updated corporate video explaining its lead drug candidate, G-202.
Sign-up for GenSpera, Inc. (GNSZ) Releases Updated Corporate Video: "GenSpera has targeted its active ingredient thapsigargin to kill only the cells we select: cancer" investment picks
Umpqua Bank , a subsidiary of Umpqua Holdings Corporation (NASDAQ:UMPQ), today announced that it will be consolidating 27 stores this year as a result of its April 2014 merger with Sterling Financial Corporation.
Sign-up for Umpqua Bank Announces Consolidation of 27 Stores as Part of Merger Integration investment picks
ATHENS, Greece, June 23, 2014 (GLOBE NEWSWIRE) -- TOP Ships Inc. (Nasdaq:TOPS) ("Top Ships" or the "Company"), an international owner and operator of modern, fuel efficient "ECO" MR tanker vessels focusing on the transportation of petroleum products, announced today the following corporate developments: Delivery of EShips Taweelah The Company took delivery of the EShips Taweelah, a 50,000 dwt fuel efficient "ECO" MR product tanker, the first of six vessels under construction in the Company's fleet.
Sign-up for TOP Ships Inc. Announces Delivery of First Newbuild Vessel investment picks
Mellanox® Technologies, Ltd.
Sign-up for InfiniBand Leads TOP500 as Most Used Interconnect Technology for High-Performance Computing investment picks
NORTHBROOK, Ill., June 23, 2014 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH) , a company enhancing medicine through targeted molecular diagnostics, today announced that it has been selected by HealthTrust as a provider of multi-target molecular diagnostic tests for the nearly 1,400 acute care facilities that are part of the HealthTrust membership.
Sign-up for Nanosphere Signs Molecular Diagnostic Supply Agreement With HealthTrust investment picks
NEW YORK (MarketWatch) -- AbbVie (ABBV) on Monday raised the midpoint of its 2014 earnings-per-share guidance by 6 cents to reflect a strong business performance in the year so far and expectations that a positive trend will continue through the rest of the year.
Sign-up for AbbVie raises outlook for 2014 investment picks
NEW YORK , June 23, 2014 /PRNewswire/ -- Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Integrys Energy Group Inc. ("Integrys" or the "Company") (NYSE: TEG) .
Sign-up for Integrys Energy Shareholder Alert - Buyout Of Integrys Energy Group Inc. (NYSE: TEG)- National Securities Law Firm Seeks Higher Price For Shareholders investment picks
Mercer announced today that it has entered into a definitive agreement to acquire a 34% stake in South Africa-based Alexander Forbes Group Holdings Limited (Alexander Forbes), becoming a key strategic shareholder in the upcoming listing of Alexander Forbes on the Johannesburg Stock Exchange (JSE). Alexander Forbes also announced today its intention to list on the JSE.
Sign-up for Mercer to Acquire 34% Strategic Stake in South Africa-Based Alexander Forbes investment picks
Nielsen (NYSE:NLSN), a leading global provider of information and insights into what consumers watch and buy, today announced that its indirect wholly-owned subsidiaries, Nielsen Finance LLC and Nielsen Finance Co., are proposing to issue $800 million aggregate principal amount of 5.00% senior notes due 2022 (the “Notes”) in a private offering that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Notes will trade interchangeably with the $750 million aggregate principal amount of 5.00% Senior Notes due 2022 issued by Nielsen Finance LLC and Nielsen Finance Co.
Sign-up for Nielsen Announces $800 Million Debt Offering investment picks
SANTA ANA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Corinthian Colleges, Inc. (Nasdaq:COCO) announced today that it has reached a memorandum of understanding with the U.S. Department of Education (the "Department") that maintains uninterrupted daily operations at its schools, until the Company and the Department finalize a more detailed transition plan.
Sign-up for Corinthian Colleges, U.S. Department of Education Agree in Principle on Transition Plan investment picks
SHREWSBURY, N.J., June 23, 2014 (GLOBE NEWSWIRE) -- InterCloud Systems, Inc. (Nasdaq:ICLD) ("InterCloud" or the "Company"), a single source provider of IT solutions through cloud platforms and professional services, today announced that the Company will be added to the Russell Microcap Index when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indices on June 27.
Sign-up for InterCloud to be Added to Russell Microcap Index investment picks
WidePoint subsidiary Soft-ex selected as an approved provider for UK Government deals MCLEAN, Va.
Sign-up for WidePoint Awarded G-Cloud 5 Framework Contract investment picks
Amaya Announces Upsize of Previously Announced Offering of Convertible Preferred Shares Canada NewsWire /NOT FOR DISSEMINATION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES/ MONTREAL , June 23, 2014 /CNW/ - Amaya Gaming Group Inc. (TSX: AYA) ("Amaya" or the "Corporation") announced today that it has upsized its previously announced private placement offering of convertible preferred shares of the Corporation (the "Convertible Preferred Shares") from treasury, on an underwritten bought-deal private placement basis, in order to meet additional demand.
Sign-up for Amaya Announces Upsize of Previously Announced Offering of Convertible Preferred Shares investment picks
MONTREAL , June 23, 2014 /PRNewswire/ - Amaya Gaming Group Inc. (TSX: AYA) ("Amaya" or the "Corporation") announced today that it has upsized its previously announced private placement offering of convertible preferred shares of the Corporation (the "Convertible Preferred Shares") from treasury, on an underwritten bought-deal private placement basis.
Sign-up for Amaya Announces Upsize of Previously Announced Offering of Convertible Preferred Shares investment picks
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced the recent appointments of three executives with extensive pharmaceutical industry experience in the areas of global quality, medical affairs, and drug safety and pharmacovigilance.
Sign-up for ARIAD Announces Three Key Appointments to Its Global Management Team investment picks
BEIJING, June 23, 2014 (GLOBE NEWSWIRE) -- ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (the "ChinaNet" or "Company"), a leading B2B (business to business) Internet technology company focusing on providing online-to-offline ("O2O") sales channel expansion services for small and medium-sized enterprises ("SMEs") and entrepreneurial management and networking services for entrepreneurs in the People's Republic of China, today announced that executives from the company participated in international brands curriculum "Systematic Creates Wealth" in Anhui Province, China on June 17 th and 18 th , 2014 to help train and promote entrepreneurs and franchise owners in the food industry.
Sign-up for ChinaNet Online Holdings Participates in Industry Event to Train Entrepreneurs and Franchise Owners investment picks
Enzo Biochem, Inc. (NYSE:ENZ) (the "Company"), along with its subsidiary Enzo Life Sciences, Inc. entered into a Settlement with PerkinElmer, Inc. and PerkinElmer Health Sciences, Inc. (NYSE:PKI) with respect to an action between the Company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817.
Sign-up for Enzo Biochem Announces Settlement Agreement with PerkinElmer investment picks
SANTA MONICA, Calif., June 23, 2014 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) , a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today announced that the underwriters of its previously announced initial public offering have exercised in full their option to purchase an additional 1,125,000 shares of Kite Pharma's common stock at the public offering price of $17.00 per share, less customary underwriting discounts and commissions.
Sign-up for Kite Pharma Announces Full Exercise of Underwriters' Option to Purchase Additional Shares investment picks
Agilysys, Inc. (Nasdaq:AGYS), a leading provider of innovative hospitality software solutions and services, today announced the preview of rGuest™ Stay, a groundbreaking property management system that is the first in a suite of applications built using the new rGuest hospitality software platform.
Sign-up for Agilysys Previews rGuest™ Stay Property Management System investment picks
PRINCETON, N.J., June 23, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc .
Sign-up for Advaxis Receives Notice of Allowance From U.S. Patent Office for Two Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy ADXS-cHER2 investment picks
Phase 1 Clinical Data Highlights Factor IXa as an Excellent Target for Anticoagulation Therapy BASKING RIDGE, N.J. , June 23, 2014 /PRNewswire/ -- Regado Biosciences, Inc. (Nasdaq: RGDO) , a biopharmaceutical company focused on the discovery and development of actively controllable aptamer therapeutics for the acute care setting, today announced the publication in the Journal of Thrombosis and Thrombolysis of data from a single escalating-dose Phase 1 clinical trial of the REG2 anticoagulation system.
Sign-up for Regado Biosciences' REG2 Demonstrates Dose and Concentration-Dependent Suppression of Thrombin Generation investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Valeant Posts Fact-Based Answers To Refute Allergan's Misleading Statements to Regado Biosciences' REG2 Demonstrates Dose and Concentration-Dependent Suppression of Thrombin Generation
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices